科特迪瓦药物警戒强化:GSK培训与导师试点项目在阿比让地区的影响
该项目于2018年9月至2020年2月在科特迪瓦阿比让地区实施,由国家级药物警戒利益相关方、GSK和PATH合作,对91家医疗机构的1427名医护人员进行培训与定期指导。实施前8个月收到33份不良事件报告,实施3个月后85份,18个月后361份,主要来自阿比让地区;但72小时内通报、因果评估和严重不良事件报告比例均低于20%,反馈率仅0.4%。
要点
- 定期培训与导师指导可提升医护人员不良事件报告数量。
- 报告时效、因果评估、严重不良事件报告及反馈环节仍需改进。
- 该项目经验可为药物警戒体系功能较弱的国家提供参考。
核心结论
- 定期药物警戒培训与导师指导改善了科特迪瓦的不良事件报告,但被动安全监测仍需进一步加强。
研究设计与样本
- 由国家级药物警戒利益相关方、GSK和PATH合作,于2018年9月至2020年2月在科特迪瓦阿比让地区实施,培训药物警戒联络点并对医护人员进行定期指导。
- 共有91家医疗机构的1427名医护人员接受培训。
主要发现
- 实施前8个月收到33份不良事件报告,其中11份(33.3%)来自阿比让地区。
- 实施后前3个月收到85份报告,其中71份(83.5%)来自阿比让地区。
- 实施18个月后累计收到361份报告,其中278份(77.0%)来自阿比让地区。
- 关键绩效指标中,中央收到报告占100%,完整报告占69.0%,48小时内录入本地药物警戒数据库占99.6%,录入全球数据库VigiBase占86.7%。
- 72小时内通报、因果评估和严重不良事件报告的比例均低于20%,向报告者反馈仅占0.4%。
关键数值与推荐
- 关键绩效指标类别包括不良事件报告数量、报告传输与数据录入效率、报告质量以及中央药物警戒单位对不良事件报告的响应质量。
- 中央收到不良事件报告比例为100%,完整报告比例为69.0%,48小时内录入本地药物警戒数据库比例为99.6%,录入VigiBase比例为86.7%。
- 72小时内通报、因果评估和严重不良事件报告比例均低于20%,向报告者反馈比例仅为0.4%。
临床怎么用
- 对医护人员开展定期药物警戒培训和导师指导可提高不良事件报告数量。
- 应针对报告时效、因果评估、严重不良事件报告和反馈环节设计改进措施。
- 其他国家可借鉴该项目经验,灵活调整以适配本地药物警戒体系需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pharmacovigilance (PV) in sub-Saharan Africa relies on passive surveillance but underreporting of adverse events (AEs) by health care professionals (HCPs) is a major challenge. A PV enhancement project was implemented to address this in Côte d'Ivoire. OBJECTIVE: To improve safety surveillance of medicines through PV training and mentoring of HCPs in selected health care facilities (HCFs). METHODS: This collaborative project between national PV stakeholders, GSK, and PATH was implemented from September 2018 to February 2020 in Abidjan region, Côte d'Ivoire. Trained PV focal points provided training and regular mentoring of HCPs. Key performance indicator (KPI) categories for AE reporting were the volume of AE reports, efficiency of report transmission and data entry, quality of reports, and quality of the central (Vigilance Unit) response to AE reports. RESULTS: Overall, 1427 HCPs at 91 HCFs were trained. In the 8 months before implementation, 33 AE reports were received versus 85 after 3 months and 361 after 18 months of implementation (71 [83.5%] and 278 [77.0%], respectively, from Abidjan). The KPIs with the highest proportions were: AE reports received centrally (100%), complete AE reports (69.0%), AE reports entered into the local PV database within 48 h (99.6%), and AE reports entered into the global database, VigiBase (86.7%). Report notification within 72 h, causality assessment, and serious AE reporting had proportions below 20%; feedback to reporters was provided for only 0.4% of reports. CONCLUSION: Regular PV trainings and mentoring improved AE reporting in Côte d'Ivoire but further enhancement is required to improve passive safety surveillance. Medicines and vaccines should be safe and effective for use in the general population. Health care professionals therefore have the responsibility to continuously monitor medicinal products and report any unwanted medical occurrence (adverse event). Training and mentoring of health care professionals can improve adverse event reporting. In Côte d’Ivoire, a training and mentoring project was implemented by GSK, PATH (a non-governmental organisation), and the Ministry of Health, with the objective of increasing adverse event reporting. Over the period of 18 months, 1427 health care professionals from 91 health care facilities in the Abidjan region received training and mentoring. Between January and August 2018, before the project began, 33 adverse event reports were submitted at the central level (to the country’s Vigilance Unit), with 11 (33.3%) from the Abidjan region. From September to December 2018, the first three months of project implementation, 85 reports were received, with 71 (83.5%) coming from the Abidjan region. This number increased to 361 by the end of the 18-month project, with 278 (77.0%) coming from the Abidjan region. Training of health care professionals therefore improved adverse event reporting, mainly from the Abidjan region but also nationwide. Assessments of the efficiency of adverse event reporting and the quality of adverse events reports received by the Vigilance Unit showed promising results, although there was room for improvement. Lessons learned from this project can flexibly serve the needs of other countries with less functional systems for reporting adverse events associated with medicinal products.
引用
- Mendoza YG, Jusot V, Adou F, et al. Enhancing Pharmacovigilance in Côte d'Ivoire: Impact of GSK's Training and Mentoring Pilot Project in the Abidjan Region. Drug Saf. 2023. PMID: 37966696. doi:10.1007/s40264-023-01368-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。